nextpoint therapeutics
be materials or any of their contents. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. For more information, go to leaps.bayer.com. Regulation (EU) 2017/1129. the world. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Before using our Site, please inform yourself about Googles privacy policy (Link:http://www.google.com/privacy.html). The investment portfolio includes more than 50 companies. Safety, Science NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. and Higher wind gusts possible.. on Bachelor of Science required, Masters of Science preferred. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in We do not knowingly collect information from minors under the age of 13 years without parental consent. Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. Protection, Health and Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. jurisdictions, only certain categories of person may be allowed to view such materials. Disseminate materials that impact or invade the privacy of others, such as photographs, video clips, sound recordings, personally identifiable information, or other materials that reveal personal, private or sensitive information about another person, without that persons consent. indirectly, in or into the United States by use of the mails or by any means or instrumentality Bayer, Meet 2021 Feb;9(2):156-169. of Bayer Global Member State, except that an offer to the public in such Relevant Member State of any securities may announcements and other documents available in electronic format on this webpage does not constitute These factors include those discussed in Bayers public reports which are available on the Bayer website at, . Please note that the Site does not alter its behavior or use practices when we receive a Do Not Track signal from your browser. Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. Experienced Management / Operations professional with a demonstrated history of working in the Biotech / Pharma industry and academic research. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations. This announcement is an advertisement and does not, under any circumstances, constitute a public China, United NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. jurisdictions. 51373 Leverkusen COVID19 vaccination required for onsite work; Exemptions for religious or medical reasons should reach out to HR for accommodations. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Wei Y, Ren X, Galbo PM Jr, et al. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. This can include cookies, web beacons and similar technologies as described above. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. Further, it does not constitute a Stories, Annual As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. or be You can use our locations menu to find Bayer country websites and Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. Report, More Get the latest business insights from Dun & Bradstreet. . Contact Us - Nextpoint Questions about Nextpoint? Learn more about & Socially Responsible Investing, Corporate It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. Order 2005 (the Order) or (ii) high net worth companies, and other persons to whom it may lawfully NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. We provide these links merely for your convenience. Portal, Countermotions Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site. Statements, Questions Phone: +49 30 468 1111, Alfred-Nobel-Str. Trainee Program for Financial Management, Internal Republic, El Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. We encourage you to review this Privacy Notice often to stay informed of how we may process your information. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. In other jurisdictions, only certain categories of person may be allowed to view such interstate or foreign commerce, or of any facility of a national securities exchange of the United We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together CAMBRIDGE, Mass. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. The securities are only available to, and any invitation, Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. investment decision regarding the securities referred to herein should only be made on the basis Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education, We do not generally collect this information, Commercial information, such a Services provided, your interaction with our Site and Services, To allow you access to our Services, to provide you with Services, to respond to questions you may have. Career Worldwide, Data find Bayer country websites and application, Your on the Bayer press portal. Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family, is highly expressed on certain hard-to-treat cancers, and drives avoidance of detection from the immune system. The Bayer brand stands for trust, reliability and quality throughout the world. Hub Langenfeld, Accelerate These electronic materials are thus extremely vulnerable to unauthorized distribution and copyright infringement. We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. Sustainability Our innovative approach integrates foundational. & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. +49 214 30 1, Mllerstrae 178 the Luxembourg Stock Exchange (www.bourse.lu). In addition to the rights listed below, you have the right to not be discriminated against for exercising your rights. Global, Bayer This announcement does not contain or constitute an offer of, or the solicitation of an offer to We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. The final prospectus, when published, will be available on the website of States and the tender offer cannot be accepted by any such use, means, instrumentality or facility Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. Leaps by Bayer, Bayer AG's impact investment arm,. Making press accepted by any such use, means, instrumentality or facility or from within the United States. Authority, United Arab Innovation, Bayer 10-01-2023 Print. in any other circumstances falling within Article 3(2) of the Prospectus Directive. Statement, Cookie local requirements that prohibit or restrict them from doing so. The candidate will collaborate with Research and Clinical Development to develop and refine NextPoints clinical translational strategy and drive its effective implementation to support our clinical programs. Sanofi Ventures is the corporate venture capital arm of Sanofi. Furthermore, where permissible, we may charge for this service. Previous study start-up and clinical monitoring experience desired. good faith and for information purposes only. Procurement Management Trainee Program, Bridging solicitation to purchase or subscribe for securities in the United States, Australia, Canada or 616 followers 500+ connections. For more information. menu, Information for The securities mentioned herein have not been, and will not be, registered under the Securities Act or subscribe for, any securities. About. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Sustainable Beef Production, Responsible Business Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. Phone: +49 214 30 1, Mllerstrae 178 Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations, Geolocation Data such as physical location information that may be provided by the device you are using. By clicking on the I AGREE button, I confirm that I am permitted Management, Code of Conduct She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. Services & Downloads, AGM NextPoint Therapeutics, a provider of precision immuno-oncology, has raised raised $80 million in Series B financing. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. Regulations, Sustainable language options. Information, Analyst expression Prospectus Directive includes any relevant implementing measure in each Relevant Member Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. CAMBRIDGE, Mass. 2021 Jul 9;6(61):9792. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. 2 Bhatt RS, Berjis A, Konge JC, et al. Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. (888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? & Rewards, Values NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. Individuals in California, the EU and certain other jurisdictions who are accessing this site and whose data we may be collecting and processing may have certain rights under applicable data protection law, including the right to request confirmation from us as to whether or not we are processing your Personal Data. Global, Data Privacy Information For Specific Processing Activities, Stem cells - The new age of medical research, Moving Non-Communicable Diseases Care Forward, Inspiring Creativity and Improving Health, EU Verification Logo against Counterfeit Drugs, New Safety Features for Prescription Medicine in Europe, Reducing Crop Protections Environmental Impact, Environmental Impact Reduction Reporting Results, Sustainable Agriculture in practice: Bayer Forward Farms, Conserving Natural Resources in Agriculture, Position on Deforestation and Forest Degradation, Raising the Bar on Crop Protection Safety Standards, Transfers of Values to Healthcare Professionals, Collaboration with Healthcare Professionals, Sustainability & Socially Responsible Investing, Duties and Activities of the Board of Management, International Trainee Program for Financial Management, International Future Leadership Program - Engineers, Global Supply Chain Management Trainee Program, International Procurement Management Trainee Program, International Future Leadership Program - Pharmaceuticals and Consumer Health Product Supply, Advanced 1 Wei Y, Ren X, Galbo PM Jr, et al. Potential, Leading Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is and Life in balance, Healthy The Bayer brand stands for trust, reliability and quality throughout the world. Tool, Innovation NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . Sports, Promotion Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. Our innovative approach integrates foundational. NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as Phone: Investing in a stronger future - for our shareholders, and for the world. Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. Last Name First Name Middle Name; Biniszkiewicz: Detlev: Street Address 1 Street Address 2; farmers to plant, grow and protect their harvests using less About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Any person who is not a relevant person should not act or rely on the The investment portfolio includes more than 50 companies. Bayer Global R&D expenses before special items amounted to 5.3 billion euros. About NextPoint TherapeuticsNextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. To learn more, visit nextpointtx.com. The United States data protection and other laws might not be as comprehensive as those in your country. Interested in finding out more?Please send your resume and cover letter to HR@nextpointtx.com. 13353 Berlin As CMO, Dr. Gandhi will oversee the clinical development of NextPoints precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. There will be no NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center Consensus, Return Read more about our economic, ecological and social challenges and opportunities. made on the basis of the securities prospectus. As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Winds SE at 15 to 25 mph. Making press announcements and other documents There will be no public In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub.